Latest filing published 28 Nov 2023 for Sangamo Therapeutics, INC, €361.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Jason D. Fontenot: trading record in brief
This profile gathers the share dealings of Jason D. Fontenot in Sangamo Therapeutics, Inc, where the filings describe the role as senior executive. We count 9 filings; the first trade dates from 25 April 2021 and the latest from 25 November 2023.
The filings describe grants, exercises and other transfers rather than trades on the open market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
The record was last updated on 28 November 2023 with a share grant (€361) in Sangamo Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Jason D. Fontenot
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,030 shares@ US$0.38210.9% of flowCommon StockSEC:0001209191-23-056783:0
- 1,029 shares@ US$0.771.9% of flowCommon StockSEC:0001209191-23-047590:0
- 1,029 shares@ US$1.333.3% of flowCommon StockSEC:0001209191-23-032907:0
- 42,750 shares0Common StockSEC:0001209191-23-016391:0
- 826 shares@ US$4.839.5% of flowCommon StockSEC:0001209191-22-025811:0
- 6,248 shares@ US$5.9084.4% of flowCommon StockSEC:0001209191-22-014172:0
6 of 6 declarations
